National Organization for Rare Disorders, Inc.


It is possible that the main title of the report Histidinemia is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • HAL deficiency
  • HIS deficiency
  • histidase deficiency
  • histidine ammonia-lyase (HAL) deficiency
  • hyperhistidinemia

Disorder Subdivisions

  • None

General Discussion

Histidinemia is a rare hereditary metabolic disorder characterized by a deficiency of the enzyme histidase, which is necessary for the metabolism of the amino acid histidine. The concentration of histidine is elevated in the blood. Excessive amounts of histidine, imidazole pyruvic acid, and other imidazole metabolism products are excreted in the urine. The majority of individuals with histidinemia have no obvious symptoms that would indicate that a person has this disorder (asymptomatic). Histidinemia is inherited as an autosomal recessive trait.


Histidinemia is considered a benign condition. For years, mental retardation and speech defects were associated with histidinemia. However, these findings are now considered coincidental and not due to the metabolic defect of histidinemia because reports of follow-up from newborn screening have demonstrated that the majority of infants with histidinemia do not develop clinical symptoms (asymptomatic). Nevertheless, clinical symptoms have been reported in some patients with histidinemia. To reconcile this with the benign findings from newborn screening, it has been suggested that histidinemia might be a risk factor for the development of CNS problems, and that such problems might develop only in an unfavorable circumstance such as an abnormal perinatal event.

Individuals with histidinemia have elevated levels of the amino acid histidine in the blood and excessive amounts of histidine, imidazole pyruvic acid, and other imidazole metabolism products in the urine. Most persons with histidinemia adapt to the presence of excessive histidine in the blood and do not suffer any ill effects.

According to the medical literature, infants born to mothers with histidinemia (maternal histinemia) have exhibited no symptoms.


Histidinemia is inherited as an autosomal recessive trait. Genetic diseases are determined by two genes, one received from the father and one from the mother.

Recessive genetic disorders occur when an individual inherits an abnormal gene for the same trait from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for for carrier parents to both pass the defective gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%.

Researchers believe that histidinemia is due to mutations of the human histidase gene (HAL) located on the long arm (q) of chromosome 12 (12q22-q24.1). Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Pairs of human chromosomes are numbered from 1 through 22, and an additional 23rd pair of sex chromosomes which include one X and one Y chromosome in males and two X chromosomes in females. Each chromosome has a short arm designated "p" and a long arm designated "q". Chromosomes are further sub-divided into many bands that are numbered. For example, "chromosome 12q22" refers to region 2, band 2 on the long arm of chromosome 12. The numbered bands specify the location of the thousands of genes that are present on each chromosome.

Affected Populations

Histidinemia is one of the most common inborn errors of metabolism. Based upon newborn screening of more than 20 million infants in several countries, histidinemia is estimated to occur in about one in 11,500 births overall. The disorder appears to be most prevalent among people of French Canadian or Japanese descent. Based upon newborn screening reports, approximately one in 8,600 infants in Quebec and one in 9,500 infants in Japan are affected by the disorder. The abnormality begins at birth and affects males and females in equal numbers. Histidinemia is now thought to be a primarily benign disorder.

Standard Therapies


In some states in the United States (e.g., New York and Massachusetts) routine screening of newborns for histidinemia was conducted through blood or urine tests. However, newborn screening for histidinemia has been discontinued. A diagnosis of histidinemia may be made based upon increased levels of histidine in the blood or urine.


Histidinemia is considered a benign, asymptomatic disorder that does not require treatment. According to the medical literature, therapy consisting of a carefully monitored histidine-restricted diet was once recommended, but is no longer called for.

Genetic counseling may also be of benefit to affected individuals and their families. Treatment is symptomatic and supportive for coincidental problems.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:




Buist NRM, Winter SC. Histidinemia. In: NORD Guide to Rare Disorders. Philadelphia, PA: Lippincott Williams & Wilkins: 2003:459.

The Metabolic and Molecular Bases of Inherited Disease. 8th Ed. New York, NY; McGraw-Hill Companies, Inc; 2001:1807-20.

Lyon G, et al., eds. Neurology of Hereditary Metabolic Diseases in Childhood. 2nd ed. New York, NY: McGraw-Hill Companies; 1996:89-91.

Levy HL, Taylor RG, McInnes RR. Disorders of histidine metabolism. Scriver CR, et al., eds.

Buyse ML., ed. Birth Defects Encyclopedia. Dover, MA: Blackwell Scientific Publications; For: The Center for Birth Defects Information Services Inc; 1990: 875.


Lam WK, et al. Histidinaemia: a benign metabolic disorder. Arch Dis Child. 74;1996:343-6.

Suchi M , et al. Molecular cloning and structural characterization of the human histidase gene (HAL). Genomics. 1995;29:98-104.

Widhalm K, Virmani K. Long-term follow-up of 58 patients with histidinemia treated with a histidine-restricted diet: no effect of therapy. Pediatrics. 1994;94:861-6.

Taylor RG, et al. Localization of histidase to human chromosome region 12q22-q24.1 and mouse chromosome region 10c2-d1. Cytogenet Cell Genet. 56;1991:178-81.

Taylor RG, et al. Molecular characterization of histidase cdnas, and sublocalization of the human histidase gene to 12q22-23, and the mouse gene to 10c2-d1. Am J Hum Genet. 45;1989:A164.

Lemieux B, et al. Newborn urine screening experience with over one million infants in the Quebec network of genetic medicine. J Inherit Metab Dis. 11;1988:45-55.

Dyme IZ, et al. Histidinemia. A case of resolution of myoclonic seizures after treatment with a low-histidine diet. Am J Dis Child. 1983;137:256-8.

Scriver CR, Levy HL. Histidinaemia. Part I: reconciling retrospective and prospective findings. Journal Inherited Metab Dis. 1983;6:51-3.

Rosenmann A, et al. Histidinaemia. Part II: impact; a retrospective study. Journal Inherited Metab Dis. 1983;6:54-7.

Coulombe JT, et al. Histidinaemia. Part III: impact; a prospective study. Journal Inherited Metab Dis. 1983;6:58-61.

Tada K, et al. Intellectual development in patients with untreated histidinemia. J Pediatr. 1982;101:562-3.Snyderman SE, et al. The nutritional therapy of histidinemia. J Pediatr. 1979;95:712-5.

Levy HL, Shih VE, Madigan PM. Routine newborn screening for histindinemia. Clinical and biochemical results. N Engl J Med. 1974;291:1214-9.


Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Histidinemia. Entry No: 235800. Last Edited October 26, 2011. Available at: http://www.ncbi.nlm.nih.gov/omim/. Accessed March 1, 2012

Orphanet. Histidinemia. http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=2157. Last Updated April 2004. Accessed March 1, 2012.


CLIMB (Children Living with Inherited Metabolic Diseases)

Climb Building

176 Nantwich Road

Crewe, CW2 6BG

United Kingdom

Tel: 4408452412173

Fax: 4408452412174

Email: enquiries@climb.org.uk

Internet: http://www.CLIMB.org.uk

NIH/National Institute of Diabetes, Digestive & Kidney Diseases

Office of Communications & Public Liaison

Bldg 31, Rm 9A06

31 Center Drive, MSC 2560

Bethesda, MD 20892-2560

Tel: (301)496-3583

Email: NDDIC@info.niddk.nih.gov

Internet: http://www2.niddk.nih.gov/

Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.